Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anastrozole + Triptorelin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anastrozole | Arimidex | Anastrozol | Aromatase Inhibitor 3 | Arimidex (anastrozole) is an aromatase inhibitor, which inhibits estrogen synthesis (PMID: 29719441). Arimidex (anastrozole) is FDA approved for postmenopausal women with hormone receptor-positive early breast cancer or advanced patients who have failed tamoxifen therapy (FDA.gov). |
Triptorelin | AY-25650|CL-118,532|Detryptoreline | Triptorelin is an analog of luteinizing-hormone-releasing hormone (LHRH), which suppresses gonadotropin secretion, leading to decreased testosterone production in males (PMID: 31500470). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05896566 | Phase II | Anastrozole + Triptorelin Giredestrant + Triptorelin Giredestrant | A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (PREcoopERA) | Recruiting | SWE | ITA | IRL | HUN | FRA | ESP | DEU | CHE | 0 |